Anti-Neoplastic Agents Market Research Report Information, by type (alkylating and alkylating-like agents, antimetabolites, antitumor antibiotics, plant alkaloids, hormonal agents, and miscellaneous agents), by end user (hospitals, clinics, research institutes, cancer rehabilitation centers and others) - Forecast to 2032

Anti-Neoplastic Agents Market Overview

Anti-Neoplastic Agents Market Size was valued at USD 137.07 Billion in 2023. The Global Anti-Neoplastic Agents industry is projected to grow from USD 154.44 Billion in 2024 to USD 363.14 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 9.97% during the forecast period (2024 - 2032). Cancer is regarded as one of the world's most critical public health issues. The early detection of cancer is critical, as the majority of patients present with advanced disease at their first clinical appointment. Anti-neoplastic drugs are regarded as a significant therapy option. Many anticancer medications have been created since the initial clinical report of chemotherapy for advanced tumors, such as Carmustine, Fludarabine, and Gemcitabine, and have effectively improved the clinical results of patients with advanced cancers. Antineoplastic medicines are treatments that prevent cancer cells from maturing and multiplying. These substances enter the human body and kill malignant cells. These drugs/agents are used in concert with surgery, radiation, and immunotherapy to treat a variety of solid malignancies, notably metastatic tumors. The Anti-Neoplastic Agents Market Growth is expanding at a reasonable rate.

After cardiovascular illnesses, cancer is the second greatest cause of mortality in the United States, and it is predicted to overtake cardiovascular diseases as the main cause of death in the future years. Malignant neoplasms accounted for 15% of fatalities globally during the historic forecast period, according to the Centers for Disease Control and Prevention (CDC), with 19.3 million additional cancer cases anticipated to be identified during the forecast period.

COVID Analysis

Countries' health systems are increasingly investing in research and development to tackle the COVID-19 pandemic. CHEMBL, ZINC, FDA-approved medicines, and molecules in clinical trials were all searched for potential compounds. Medications for the treatment of COVID-19 are being developed by screening both novel and existing drugs for their potential to reduce symptoms and stop viral replication. As a result of the ongoing epidemic, the anti-neoplastic agents market is likely to benefit due to the need to find a cure for COVID-19. Also, as per the American Cancer Society, around 1.8 million new cancer cases were predicted to be diagnosed during the historic prediction period, with approximately 606,520 cancer deaths occurring in the United States. As a result, the rising prevalence of a wide range of diseases across all age groups, as well as their global impact, are driving demand for the market.

Anti-Neoplastic Agents Market Dynamics

Drivers

The growing number of new cases of neoplasms around the world, as well as the growing demand for low-cost medicines to cure them, has spurred the rise of the Anti-Neoplastic Agents Market Share. According to the World Health Organization, one in every five men and one in every six women will develop cancer throughout their lifetime, with one in every eight men and one in every eleven women dying from it. Several factors contribute to the rising cancer burden, including population increase and aging, as well as shifting prevalence of certain cancers connected to social and economic development. The number of government initiatives aimed at improving animal health conditions among cancer sufferers is growing. The rising frequency of cancer, as well as the number of fatalities caused by cancer, has fueled anti-neoplastic agents market growth. Increasing investment in cancer research by multinational corporations due to rising cancer prevalence is predicted to drive the market over the forecast period. Furthermore, the market's expected rise is related to rising cancer cases and the desire for cost-effective medicines over the forecasted timeframe.

Restraints

The varied nature of cancer and the high development cost of anti-neoplastic drugs are the factors restricting the market growth. Higher development costs for neoplastic agents, as well as the varied character of cancer, can function as market restrictions. Nonetheless, a lack of understanding of cancer symptoms in rising and developing economies, as well as underdeveloped countries, would represent a danger to the anti-neoplastic agents market outlook over the projection period. However, these are several constraints and hurdles that could stifle market expansion during the forecast period.

The Anti-Neoplastic Agents Market report provides detailed market data on technology, prognosis, and treatments. Prevalence, incidence, mortality, and adherence rates are just a few of the data variables available on the market today. For better drug candidate identification, modern technologies such as high throughput, bioinformatics, and combinatorial chemistry are being used more frequently. Anti-Neoplastic Agents have progressed greatly as a result of new technology, allowing the procedure to become more refined, precise, and time-consuming. Artificial intelligence systems are increasingly being used in disease diagnosis and treatment design, and this trend is projected to continue in the coming years. Over the forecast period, it is expected to contribute to market growth.

Anti-Neoplastic Agents Market Segment Overview

The Global Gangrene Market is further bifurcated into various segments depending on various factors to help the market to grow as per the predicted CAGR growth by the end of the forecast period. The Global Gangrene Market is segmented based on the following:

Based on the type, the market has been segmented as follows:

• Alkylating and Alkylating-Like Agents


• Antimetabolites


• Antitumor Antibiotics


• Plant Alkaloids


• Hormonal Agents


• Miscellaneous Agents

Based on the end-users, the market has been segmented as follows:

• Hospitals


• Clinics


• Research Institutes


• Cancer Rehabilitation Centers


• Others

Anti-Neoplastic Agents Market Regional Classification

Anti-neoplastic agents have the largest market in the Americas. By the conclusion of the forecast period, the market for antineoplastic drugs in the Americas is predicted to reach significant value. Because of the high prevalence of malignant neoplasm, North America will continue to lead the worldwide anti-neoplastic agents market.

Anti-neoplastic agents' second-largest market is Europe. According to Cancer Research UK, 605 persons per 100,000 in the general population were diagnosed with cancer during the historic predicted period. In the market for anti-neoplastic drugs, the Asia-Pacific region is predicted to develop at the fastest rate.

Anti-Neoplastic Agents Market Competitive Landscape

To stay competitive in the worldwide market, market players are using new tactics such as new product development, joint ventures, mergers and acquisitions, and geographic expansion. Some of the major key players in the market are Amgen Inc., Boehringer Ingelheim GmbH, Oxford BioTherapeutics Ltd., Bayer AG, Aspen Holdings, Pfizer Inc., F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Baxter Healthcare Corporation, Teva Pharmaceutical Industries Ltd, Genentech Inc., AbbVie Inc., ImmunityBio, Inc., and others.

Recent Developments

Boehringer Ingelheim and Oxford BioTherapeutics Ltd. have formed cooperation to find additional selective targets for strategic cancer indications to develop first-in-class cancer medicines. Using its T-cell engager, cancer vaccine, and oncolytic virus platforms, the company will employ OBT's OGAP platform to uncover novel target opportunities for new immune therapeutics.

ImmunityBio, Inc. and NantKwest, Inc. combined in March 2021 to form a premier late-stage cell therapy and immunotherapy firm specializing in oncology and infectious illnesses. ImmunityBio, Inc. is the name of the united company (NASDAQ: IBRX).

BI 905711, a bi-specific and tetravalent therapeutic antibody, has been approved by Boehringer Ingelheim for patients with advanced gastrointestinal (GI) malignancies. As a result of the advancement, the company will be able to create additional new medications to treat diseases that have a high unmet demand among cancer patients.

Anti-Neoplastic Agents Market Report Overview

The market is divided into three categories i.e., type, end-users, and region. Leading Anti-Neoplastic Agents Companies are profiled in detail in the research. COVID-19 Recovery Scenarios are also included. Market overview, market segments, new developments, competitive landscape, strategic recommendations, key company analysis, market opportunities, drivers, restraints, company profiling, geographical analysis, and analytical overview of the market are all covered in-depth in this report. Some of the factors driving the growth of the anti-neoplastic agents market include increased disease awareness and concern, as well as increased demand for anti-neoplastic agents.